There are currently 467 clinical trials in Buffalo, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Roswell Park Cancer Institute, University at Buffalo, Roswell Park Comprehensive Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
NCT03727061
Recruiting
This phase I trial studies the side effects of interstitial photodynamic therapy (I-PDT) in treating patients with head and neck cancer that has spread to other parts of the body or that has come back. Interstitial photodynamic therapy uses a light-sensitive drug called porfimer sodium. This drug is activated by laser light delivered through special fibers into the tumor. In this study the doctors will evaluate the safety of I-PDT and determine the potentially effective light setting in this tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Recurrent Head and Neck Carcinoma, Locally Advanced Head and Neck Carcinoma
Register for Updates
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
NCT05168163
Recruiting
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibod... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Register for Updates
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
NCT04682158
Recruiting
This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT and will be considered separately as a single arm prospective cohort
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Esophageal Adenocarcinoma
Register for Updates
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NCT05787496
Recruiting
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
Register for Updates
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT03463954
Recruiting
Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Buffalo General Medical Center, Buffalo, New York
Conditions: Malignant Neoplasm of Breast
Register for Updates
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
NCT05172960
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).
Gender:
All
Ages:
All
Trial Updated:
03/29/2024
Locations: University at Buffalo - Kaleida Health, Buffalo, New York
Conditions: Aortic Stenosis, Severe
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: University at Buffalo, Buffalo, New York
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
NCT05003843
Recruiting
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Kaleida University at Buffalo, Buffalo, New York
Conditions: Deep Vein Thrombosis, DVT
Register for Updates
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT05231122
Recruiting
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, an... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
Register for Updates
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT05143840
Recruiting
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy and safety of asciminib in newly diagnosed CML-CP. Patients will receive asciminib 80 mg orally once daily during the single asciminib phase. Response is determined by PCR (polymerase chain reaction) blood test during the study. Patients who have not... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Register for Updates
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
NCT05030272
Recruiting
The study team will conduct a Multisite Randomized Controlled Trial to evaluate the advantages and disadvantages of two approaches for quitting smoking among people with serious mental illness (SMI). The study will compare a novel app tailored to people with SMI, Quit on the Go, to a standard of care smoking cessation intervention. We will test the effectiveness of the Quit on the Go app, an intervention that has demonstrated feasibility and acceptability in the target population, as a tool for... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: University at Buffalo, Buffalo, New York
Conditions: Tobacco Use Disorder, Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Recurring Major Depressive Disorder, Persistent Depressive Disorder
Register for Updates
Social Workers Addressing Firearm Risk
NCT05784662
Recruiting
Aim 2: Evaluate the preliminary efficacy of the SAFR intervention using a randomized controlled trial. An additional 100 practicing social workers (excluding participants from Aim 1) will be recruited, with n = 50 allocated to each arm of the study utilizing block randomization. Participants in the control arm will receive invitations to all surveys but not to the SAFR intervention itself. We will utilize the validated measures from Aim 1 to assess changes on study variables. Results will be ana... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/22/2024
Locations: Online Only, Buffalo, New York
Conditions: Gun Violence Prevention
Register for Updates